IntoCell, Inc.
Develops and licenses proprietary ADC platform technologies for cancer & immune therapies.
287840 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 대덕구 신일동로 101, 대전광역시
- Website:
- https://intocell.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
IntoCell, Inc. is a biotechnology company specializing in the research and development of novel biopharmaceuticals. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) platform technologies, including its OHPAS™ linker and Payload Modification Technology. IntoCell leverages these platforms to develop targeted therapies for cancer and immunological disorders. The company's business model is centered on the commercialization and transfer of its innovative ADC technologies to global partners in the pharmaceutical industry.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for IntoCell, Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all IntoCell, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for IntoCell, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
